Q3 FY2026
Filed Nov 3, 2026Philips reports Q3 2026 comparable order intake up 8%, comparable sales up 3% and adjusted EBITA margin up 70 basis points to 13.0%, while income from operations fell to EUR 165 million after a EUR 288 million Respironics DOJ settlement provision; full-year 2026 outlook reiterated
Comparable order intake (8%), comparable sales growth (3%) and adjusted EBITA margin (13.0%, up 70 basis points) are solid, and free cash flow rose to EUR 384 million from EUR 172 million. Income from operations fell to EUR 165 million from EUR 330 million, mainly due to the EUR 288 million Respironics DOJ settlement provision as stated by the company, and net income fell to EUR 28 million from EUR 187 million. The full-year 2026 outlook was reiterated.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Sales, Q3 2026 (nominal growth)GAAP | €4.39B | – | 2% |
| Comparable sales growth, Q3 2026non-GAAP | 3% | – | – |
| Comparable order intake, Q3 2026other | 8% | – | – |
| Cost of sales, Q3 2026GAAP | −€2.35B | – | – |
| Gross margin, Q3 2026GAAP | €2.04B | – | – |
| Gross margin as % of sales, Q3 2026GAAP | 46% | – | – |
| Selling expenses, Q3 2026GAAP | −€1.02B | – | – |
| General and administrative expenses, Q3 2026GAAP | −€158M | – | – |
| Research and development expenses, Q3 2026GAAP | −€410M | – | – |
| Other business income, Q3 2026GAAP | €2M | – | – |
| Other business expenses, Q3 2026GAAP | −€293M | – | – |
| Income from operations, Q3 2026GAAP | €165M | – | decreased by EUR 165 million |
| Income from operations as % of sales, Q3 2026GAAP | 4% | – | – |
| Financial income (expenses), net, Q3 2026GAAP | −€42M | – | – |
| Results of associates, Q3 2026GAAP | −€1M | – | – |
| Income tax (expense) benefit, Q3 2026GAAP | −€92M | – | – |
| Income from continuing operations, Q3 2026GAAP | €30M | – | – |
| Net income, Q3 2026GAAP | €28M | – | – |
| EBITA, Q3 2026non-GAAP | €216M | – | – |
| EBITA as % of sales, Q3 2026non-GAAP | 4.9% | – | – |
| Adjusted EBITA, Q3 2026non-GAAP | €569M | – | – |
| Adjusted EBITA margin, Q3 2026non-GAAP | 13.0% | – | increased 70 basis points |
| Adjusted EBITDA, Q3 2026non-GAAP | €772M | – | – |
| Adjusted EBITDA as % of sales, Q3 2026non-GAAP | 17.6% | – | – |
| Income from continuing operations attributable to shareholders per diluted share, Q3 2026GAAP | EUR 0.03 | – | – |
| Net income attributable to shareholders per diluted share, Q3 2026GAAP | EUR 0.03 | – | – |
| Adjusted income from continuing operations per diluted share (Adjusted EPS), Q3 2026non-GAAP | EUR 0.40 | – | – |
| Adjusted income from continuing operations attributable to shareholders, Q3 2026non-GAAP | €395M | – | – |
| Restructuring, acquisition-related and other items, Q3 2026non-GAAP | €353M | – | – |
| Respironics DOJ settlement provision, Q3 2026GAAP | €288M | – | – |
| Net cash flows from operating activities, Q3 2026GAAP | €544M | – | – |
| Free cash flow, Q3 2026non-GAAP | €384M | – | – |
| Net capital expenditures, Q3 2026GAAP | −€160M | – | – |
| Dividends paid to shareholders, Q3 2026GAAP | −€37M | – | – |
| Ending cash balance, September 30, 2026GAAP | €2.75B | – | – |
| Net debt : group equity ratio, September 30, 2026non-GAAP | 32:68 | – | – |
| Sales, January to September 2026 (nominal growth)GAAP | €12.66B | – | (1%) |
| Comparable sales growth, January to September 2026non-GAAP | 3% | – | – |
| Gross margin, January to September 2026GAAP | €5.96B | – | – |
| Selling expenses, January to September 2026GAAP | −€3.08B | – | – |
| General and administrative expenses, January to September 2026GAAP | −€490M | – | – |
| Research and development expenses, January to September 2026GAAP | −€1.29B | – | – |
| Other business income, January to September 2026GAAP | €233M | – | – |
| Other business expenses, January to September 2026GAAP | −€318M | – | – |
| Income from operations, January to September 2026GAAP | €1.01B | – | – |
| Net income, January to September 2026GAAP | €560M | – | – |
| Income from continuing operations per diluted share, January to September 2026GAAP | EUR 0.58 | – | – |
| Adjusted EPS (diluted), January to September 2026non-GAAP | EUR 1.12 | – | – |
| Adjusted EBITA, January to September 2026non-GAAP | €1.64B | – | – |
| Adjusted EBITA margin, January to September 2026non-GAAP | 12.9% | – | – |
| Adjusted EBITDA, January to September 2026non-GAAP | €2.25B | – | – |
| Net cash flows from operating activities, January to September 2026GAAP | €1.11B | – | – |
| Free cash flow, January to September 2026non-GAAP | €635M | – | – |
| Dividends paid to shareholders, January to September 2026GAAP | −€358M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Diagnosis & TreatmentComparable sales growth was flat. Mid-single-digit growth in Image Guided Therapy was offset by a mid-single-digit decline in Precision Diagnosis, mainly due to phasing of Ultrasound sales and lower sales in China. Adjusted EBITA was EUR 255 million (prior year EUR 246 million), margin 12.3% (11.8%), improved by 50 basis points, mainly driven by gross margin from innovation and productivity measures, partly offset by cost inflation. Comparable order intake growth was described as strong, driven by Diagnosis & Treatment. | €2.08B | – | 0% nominal sales growth (0% comparable) |
| Connected CareComparable sales increased by 5%, driven by growth in all Businesses. Adjusted EBITA was EUR 157 million (prior year EUR 137 million), margin 13.3% (11.4%), improved by 190 basis points, mainly driven by higher sales, gross margin, favorable mix effects, and productivity measures, partly offset by cost inflation. Income from operations was EUR (195) million (prior year EUR 12 million), with restructuring, acquisition-related and other items of EUR 327 million, mainly including the EUR 288 million Respironics DOJ settlement provision and EUR 34 million of other Respironics-related charges. | €1.18B | – | (2%) nominal sales growth (5% comparable) |
| Personal HealthComparable sales increased by 8%, driven by double-digit growth in Growth geographies and mid-single-digit growth in Mature geographies. Adjusted EBITA was EUR 168 million (prior year EUR 151 million), margin 17.7% (17.1%), improved by 60 basis points, mainly driven by higher sales and productivity measures, partly offset by advertising and promotion spend. Income from operations was EUR 165 million (prior year EUR 143 million). | €953M | – | 8% nominal sales growth (8% comparable) |
| OtherSegment Other sales increased by EUR 39 million, mainly reflecting activities related to a divestment, which is excluded from comparable sales growth. Adjusted EBITA was EUR (12) million (prior year EUR (3) million), decreased by EUR 9 million, mainly due to phasing in central costs. | €179M | – | increased by EUR 39 million |
| Western Europe (geography)Mature geographies comparable sales showed 3% growth, mainly driven by Western Europe. | €971M | – | 4% nominal (5% comparable) |
| North America (geography)Reported as part of Mature geographies. No further driver stated in the filing. | €1.86B | – | 2% nominal (1% comparable) |
| Other mature geographiesReported as part of Mature geographies. No further driver stated in the filing. | €317M | – | (1%) nominal (3% comparable) |
| Mature geographiesComparable sales in Mature geographies showed 3% growth, mainly driven by Western Europe. | €3.15B | – | 2% nominal (3% comparable) |
| Growth geographiesGrowth geographies showed 3% comparable sales growth, mainly driven by Central Eastern Europe, the Indian subcontinent and certain markets in the Southeast Asia and Pacific region. | €1.24B | – | 2% nominal (3% comparable) |
FY2026 (full year, reiterated) outlook
- RevenueComparable sales growth: 3%-4.5%
- NoteAdjusted EBITA margin: 13.5%-14.0%, including a US tariff refund benefit of approximately 1%
- NoteFree cash flow: EUR 1.5-1.7 billion, including a net US tariff refund benefit of approximately EUR 200 million
- NoteThe outlook includes currently known tariffs and assumes payment of the US Department of Justice settlement in the first quarter of 2027
- NoteThe outlook excludes other ongoing Philips Respironics-related proceedings, including the investigation by the US State Attorneys General
Capital returns
- Dividends paid to shareholders were EUR (37) million in Q3 2026 (Q3 2025: EUR (33) million) and EUR (358) million year to date (January to September 2025: EUR (328) million). The company states that the Q3 2026 payment reflects the payment of the dividend-related withholding tax.
- Purchase of treasury shares was EUR (69) million January to September 2026; no treasury share purchases are printed for Q3 2026.
- Philips issued EUR 650 million fixed rate notes due 2034 under its European Medium Term Note program in Q3 2026. The notes are described as the healthcare industry's first EU Green Bond under the new European Green Bond Standard and were 2.7 times oversubscribed. An amount equivalent to the gross proceeds will be used to finance taxonomy-aligned economic activities.
- The company states it is delivering EUR 170 million in net savings in Q3 2026 and EUR 427 million year to date under its productivity program, and remains on track to deliver EUR 1.5 billion in savings under its 2026-2028 productivity program.
What drove it
- Comparable order intake grew 8%, driven by strong growth in Diagnosis & Treatment, per the company.
- Comparable sales grew 3%, driven by Personal Health and Connected Care, per the company.
- Adjusted EBITA margin increased 70 basis points to 13.0%, mainly driven by higher sales, higher gross margin and productivity measures, partly offset by cost inflation, per the company.
- Net income decreased mainly due to income from operations, partly offset by lower net financial expenses, per the company.
- Diagnosis & Treatment comparable sales were flat: Image Guided Therapy growth was offset by a decline in Precision Diagnosis, mainly due to phasing of Ultrasound sales and lower sales in China, as previously communicated at Q2, per the company.
- Connected Care adjusted EBITA margin improved 190 basis points, mainly driven by higher sales, gross margin, favorable mix effects and productivity measures, per the company.
- Growth geographies comparable sales grew 3%, mainly driven by Central Eastern Europe, the Indian subcontinent and certain markets in the Southeast Asia and Pacific region.
Concerns
- Income from operations was EUR 165 million versus EUR 330 million in Q3 2025, decreased by EUR 165 million, mainly due to the EUR 288 million Respironics DOJ settlement provision, per the company.
- Net income was EUR 28 million versus EUR 187 million in Q3 2025. Income from continuing operations was EUR 30 million versus EUR 188 million.
- Income tax expense increased by EUR 5 million, mainly due to the tax treatment of the Respironics DOJ settlement provision in Q3 2026, per the company.
- Diagnosis & Treatment comparable sales were flat, with a mid-single-digit decline in Precision Diagnosis and a mid-single-digit decline in Growth geographies within that segment.
- Restructuring, acquisition-related and other items were EUR 353 million in Q3 2026 versus EUR 122 million in Q3 2025, including EUR 34 million of other Respironics-related charges.
- The Respironics investigation by the US State Attorneys General remains ongoing and is excluded from the outlook, per the company.
- Other mature geographies recorded nominal sales decline of (1%) in Q3 2026 while comparable sales grew 3%.
What to watch
- Finalization of the documentation for the Respironics agreement in principle with the US Department of Justice, and the expected payment in the first quarter of 2027.
- Outcome of the other Philips Respironics-related proceedings, including the investigation by the US State Attorneys General, which the outlook excludes.
- Phasing of Ultrasound sales and China sales in Diagnosis & Treatment, given flat comparable sales in Q3 2026.
- Conversion of the 8% comparable order intake into sales, as the company cites a strong order book.
- Delivery of the full-year outlook: comparable sales growth of 3%-4.5%, adjusted EBITA margin of 13.5%-14.0% including a tariff refund benefit of approximately 1%, and free cash flow of EUR 1.5-1.7 billion including a net tariff refund benefit of approximately EUR 200 million.
- Progress on the EUR 1.5 billion savings target under the 2026-2028 productivity program, with EUR 427 million delivered year to date.
- Q4 2026 results, including the impact of the tariff refund benefits assumed in the outlook.
Balance sheet and cash flow
- Free cash flow was EUR 384 million in Q3 2026 (Q3 2025: EUR 172 million) and EUR 635 million January to September 2026 (January to September 2025: EUR (688) million).
- Net cash flows from operating activities were EUR 544 million in Q3 2026 (Q3 2025: EUR 327 million). The company states this increased mainly due to higher cash earnings and lower working capital outflows.
- Changes in debt were EUR 603 million in Q3 2026 (Q3 2025: EUR (42) million). The company states this includes the new EUR green bonds issuance of EUR 646 million, partly offset by debt repayments.
- Ending cash balance was EUR 2,751 million at September 30, 2026 (December 31, 2025: EUR 2,794 million; September 30, 2025: EUR 1,912 million).
- Total debt was EUR 8,139 million at September 30, 2026 (December 31, 2025: EUR 8,084 million), comprising long-term debt of EUR 6,985 million and short-term debt of EUR 1,154 million. Net debt was EUR 5,387 million (December 31, 2025: EUR 5,290 million).
- Group equity was EUR 11,609 million at September 30, 2026 (December 31, 2025: EUR 10,990 million). Total assets were EUR 28,027 million (December 31, 2025: EUR 26,944 million).
- Net debt to group equity ratio was 32:68 at September 30, 2026, unchanged from December 31, 2025.
Analysis
Philips reported third-quarter 2026 sales of EUR 4,393 million, up 2% on a nominal basis and 3% on a comparable basis, against comparable order intake growth of 8%. Gross margin rose to EUR 2,040 million (46% of sales) from EUR 1,911 million (44%) in Q3 2025, and selling, general and administrative and R&D expense lines were each lower than or close to the prior-year quarter. Adjusted EBITA rose to EUR 569 million and the margin to 13.0%, an increase of 70 basis points, which the company attributes to higher sales, higher gross margin and productivity measures, partly offset by cost inflation. On a reported basis, however, income from operations fell to EUR 165 million from EUR 330 million, and net income to EUR 28 million from EUR 187 million. The company attributes the decline in income from operations mainly to the EUR 288 million Respironics DOJ settlement provision.
By segment, Diagnosis & Treatment was flat on comparable sales, with Image Guided Therapy growth offset by a mid-single-digit decline in Precision Diagnosis, which the company links to Ultrasound phasing and lower sales in China. Its adjusted EBITA margin rose to 12.3%. Connected Care grew comparable sales 5% and lifted its adjusted EBITA margin to 13.3%, but its reported income from operations was EUR (195) million after the Respironics-related charges booked in that segment, compared with EUR 12 million in Q3 2025. Personal Health grew comparable sales 8% with an adjusted EBITA margin of 17.7%. Among geographies, Mature geographies grew comparable sales 3%, led by Western Europe, while Growth geographies grew 3%, led by Central Eastern Europe, the Indian subcontinent and parts of Southeast Asia and Pacific.
Cash generation improved. Net cash from operating activities was EUR 544 million against EUR 327 million, and free cash flow was EUR 384 million against EUR 172 million. Year to date, free cash flow was EUR 635 million against EUR (688) million a year earlier. The company issued EUR 650 million of fixed rate notes due 2034 under the European Medium Term Note program, described as the healthcare industry's first EU Green Bond under the European Green Bond Standard and 2.7 times oversubscribed. Net debt was EUR 5,387 million at September 30, 2026, and the net debt to group equity ratio stood at 32:68, unchanged from year end. Ending cash was EUR 2,751 million. Dividends paid in Q3 were EUR (37) million, which the company says reflects the payment of a dividend-related withholding tax.
On Respironics, Philips reached an agreement in principle with the US Department of Justice to resolve the criminal and civil investigations. The company recorded a EUR 288 million provision in Q3 2026, with payment expected in the first quarter of 2027 and subject to finalization of documentation. The Enterprise Chamber of the Amsterdam Court of Appeal denied requests from certain investors for an investigation into the affairs of Philips related to the recall. Other Respironics-related charges of EUR 34 million were also recorded in the quarter, and the outlook excludes the separate State Attorneys General investigation.
The full-year 2026 outlook was reiterated, not changed: comparable sales growth of 3%-4.5%, adjusted EBITA margin of 13.5%-14.0% including a US tariff refund benefit of approximately 1%, and free cash flow of EUR 1.5-1.7 billion including a net US tariff refund benefit of approximately EUR 200 million. Year to date, comparable sales growth is 3% and the adjusted EBITA margin is 12.9%, compared with 11.2% a year earlier. The prior-period outlook was not supplied with this filing, so the reiteration cannot be checked line by line against an earlier range.
Management, verbatim
We delivered an excellent 8% comparable order intake, led by broad-based order momentum in Diagnosis & Treatment, and 3% comparable sales growth in the third quarter, led by Personal Health and Connected Care.
Roy Jakobs, CEO, Royal Philips
The Respironics agreement in principle with the US Department of Justice marks an important step in this process.
Roy Jakobs, CEO, Royal Philips
Our year-to-date results, together with our strong order book, give us confidence in delivering our full-year outlook and achieving our medium-term ambitions.
Roy Jakobs, CEO, Royal Philips
Not in the filing
stated, not guessed- The previous release outlook was not provided, so vs_prior_guidance is empty and the reiteration is taken from the filing text only.
- Sequential (quarter over quarter) percentage changes are not printed for any metric; qoq_change is null throughout.
- Prior-quarter (Q2 2026) values for several income statement lines (selling, G&A, R&D, other business income and expenses, financial items, tax) are not printed in the statistics table and are null.
- Prior-quarter free cash flow, operating cash flow and restructuring figures are not printed in the statistics table and are null.
- Prior-year EBITA and adjusted EBITA margin changes in basis points are not printed for all segments; segment prior-quarter values are not printed.
- The year-over-year change in comparable sales for Q3 2025 is not printed; only the Q3 2025 comparable growth rate is shown in prior_year.
- Group-level year-over-year change in adjusted EBITDA margin is not printed; yoy_change is null.
- Net debt, total debt, group equity and total assets for September 30, 2025 are not printed; the December 31, 2025 comparisons are given in balance_sheet_cash_flow rather than in prior_year fields.
- Revenue by business within Connected Care and Personal Health is not broken out in the filing.
- Dollar or other currency translations are not provided; all figures are in EUR as printed.
- Share repurchase amounts for the prior-year year-to-date period are shown as a dash in the filing and are not reported as figures.
- Full-year 2026 actuals and Q4 2026 figures are not reported in this filing.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.